6 research outputs found
ΠΠ°ΡΠ°Π²Π΅ΡΡΠ΅Π±ΡΠ°Π»ΡΠ½Π°Ρ Π±Π»ΠΎΠΊΠ°Π΄Π° ΠΏΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π·Π°ΠΊΡΡΡΠΎΠΉ ΡΡΠ°Π²ΠΌΠΎΠΉ Π³ΡΡΠ΄ΠΈ
The study was conducted in the Thoracoabdominal Department of the N.V. Sklifosovsky Research Institute for Emergency Medicine to explore the role of paravertebral block in the treatment of blunt chest trauma. The study included 715 patients with isolated chest trauma hospitalized between January 1, 2020 and August 2021. 55 patients received analgesic therapy in the form of paravertebral block. The comparison group included 660 patients who did not undergo paravertebral block, in their case pain relief was provided by systemic administration of analgesics. The compared groups did not differ significantly in sex and age composition. There were also no differences in the frequency of chronic diseases and interpleural complications. There were no significant complications during the block. The comparison revealed a significant decrease in the incidence of pleurisy and a shorter length of stay in hospital. Paravertebral block is an effective and safe method of pain management for patients with blunt chest trauma. The use of this technique reduces the incidence of post-traumatic pleurisy and duration of hospitalization.ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ Π² ΡΠΎΡΠ°ΠΊΠΎΠ°Π±Π΄ΠΎΠΌΠΈΠ½Π°Π»ΡΠ½ΠΎΠΌ ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈΠΈ ΠΠΠ Π‘Π ΠΈΠΌ. Π.Π. Π‘ΠΊΠ»ΠΈΡΠΎΡΠΎΠ²ΡΠΊΠΎΠ³ΠΎ Ρ ΡΠ΅Π»ΡΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠ°Π²Π΅ΡΡΠ΅Π±ΡΠ°Π»ΡΠ½ΠΎΠΉ Π±Π»ΠΎΠΊΠ°Π΄Ρ. ΠΡΠ»ΠΎ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 715 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΡΠ°Π²ΠΌΠΎΠΉ Π³ΡΡΠ΄ΠΈ, Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π² ΡΠΊΡΡΡΠ΅Π½Π½ΠΎΠΌ ΠΏΠΎΡΡΠ΄ΠΊΠ΅ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ Ρ 1 ΡΠ½Π²Π°ΡΡ 2020 ΠΏΠΎ Π°Π²Π³ΡΡΡ 2021 Π³ΠΎΠ΄Π°; 55 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π² Ρ
ΠΎΠ΄Π΅ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠΎΠ»ΡΡΠΈΠ»ΠΈ ΠΎΠ±Π΅Π·Π±ΠΎΠ»ΠΈΠ²Π°ΡΡΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π² Π²ΠΈΠ΄Π΅ ΠΏΠ°ΡΠ°Π²Π΅ΡΡΠ΅Π±ΡΠ°Π»ΡΠ½ΠΎΠΉ Π±Π»ΠΎΠΊΠ°Π΄Ρ. Π Π³ΡΡΠΏΠΏΡ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Π²ΠΊΠ»ΡΡΠΈΠ»ΠΈ 660 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΊΠΎΡΠΎΡΡΠΌ Π½Π΅ Π²ΡΠΏΠΎΠ»Π½ΡΠ»ΠΈ ΠΏΡΠΎΠ²ΠΎΠ΄Π½ΠΈΠΊΠΎΠ²ΡΡ Π±Π»ΠΎΠΊΠ°Π΄Ρ, ΠΎΠ±Π΅Π·Π±ΠΎΠ»ΠΈΠ²Π°Π½ΠΈΠ΅ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°Π»ΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΡΠΌ Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅ΠΌ Π°Π½Π°Π»ΡΠ³Π΅ΡΠΈΠΊΠΎΠ². Π‘ΡΠ°Π²Π½ΠΈΠ²Π°Π΅ΠΌΡΠ΅ Π³ΡΡΠΏΠΏΡ Π·Π½Π°ΡΠΈΠΌΠΎ Π½Π΅ ΠΎΡΠ»ΠΈΡΠ°Π»ΠΈΡΡ ΠΏΠΎ ΠΏΠΎΠ»ΠΎΠ²ΠΎΠΌΡ ΠΈ Π²ΠΎΠ·ΡΠ°ΡΡΠ½ΠΎΠΌΡ ΡΠΎΡΡΠ°Π²Ρ. ΠΡΠ»ΠΈΡΠΈΠΉ Π² ΡΠ°ΡΡΠΎΡΠ΅ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΠΈ ΠΈΠ½ΡΡΠ°ΠΏΠ»Π΅Π²ΡΠ°Π»ΡΠ½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΡΠ°ΠΊΠΆΠ΅ Π½Π΅ Π±ΡΠ»ΠΎ. ΠΠ½Π°ΡΠΈΠΌΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΠΏΡΠΈ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΠΈ Π±Π»ΠΎΠΊΠ°Π΄Ρ Π½Π΅ ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΎΡΡ. ΠΡΠΈ ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Π²ΡΡΠ²Π»Π΅Π½ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠ΅ ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ°ΡΡΠΎΡΡ ΠΏΠ»Π΅Π²ΡΠΈΡΠ° ΠΈ Π±ΠΎΠ»Π΅Π΅ ΠΊΠΎΡΠΎΡΠΊΠΎΠ΅ Π²ΡΠ΅ΠΌΡ Π½Π°Ρ
ΠΎΠΆΠ΄Π΅Π½ΠΈΡ Π² ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ΅. ΠΠ°ΡΠ°Π²Π΅ΡΡΠ΅Π±ΡΠ°Π»ΡΠ½Π°Ρ Π±Π»ΠΎΠΊΠ°Π΄Π° ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΎΠ±Π΅Π·Π±ΠΎΠ»ΠΈΠ²Π°Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π·Π°ΠΊΡΡΡΠΎΠΉ ΡΡΠ°Π²ΠΌΠΎΠΉ Π³ΡΡΠ΄ΠΈ. ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΠΎΠΉ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠΈ ΡΠ½ΠΈΠΆΠ°Π΅Ρ ΡΠ°ΡΡΠΎΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΏΠΎΡΡΡΡΠ°Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠ»Π΅Π²ΡΠΈΡΠ° ΠΈ ΡΡΠΊΠΎΡΡΠ΅Ρ Π²ΡΠΏΠΈΡΠΊΡ Π±ΠΎΠ»ΡΠ½ΡΡ
Π’ΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΡ Π»Π΅Π³ΠΊΠΈΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ ΡΠΌΡΠΈΠ·Π΅ΠΌΠΎΠΉ Π½Π° ΡΠΎΠ½Π΅ Π΄Π΅ΡΠΈΡΠΈΡΠ° Ξ±1-Π°Π½ΡΠΈΡΡΠΈΠΏΡΠΈΠ½Π°
The condition of patients with chronic lung diseases is gradually deteriorating despite modern drug therapy and often progresses to severe respiratory failure. Thus, it is important to consider other options, including surgical methods, to help such patients. The aim of the study is to demonstrate potential additional pharmacological and surgical treatment algorithms for chronic obstructive pulmonary disease (COPD) associated with Ξ±1-anti-trypsin (A1AT) deficiency. Results. The analysis of long-term medical history (from the onset to the terminal stage of the respiratory failure) of a patient with A1AT deficiency was performed. Conclusion. Patients with COPD associated with A1AT deficiency require combination inhaled controller therapy and augmentation therapy with a1-proteinase inhibitor. Patients with terminal stage of the disease need lung transplantation unless they have any contraindications.ΠΠ΅ΡΠΌΠΎΡΡΡ Π½Π° ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ ΠΌΠ΅Π΄ΠΈΠΊΠ°ΠΌΠ΅Π½ΡΠΎΠ·Π½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ, ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ ΠΌΠ½ΠΎΠ³ΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ Π»Π΅Π³ΠΊΠΈΡ
ΠΏΠΎΡΡΠ΅ΠΏΠ΅Π½Π½ΠΎ ΡΡ
ΡΠ΄ΡΠ°Π΅ΡΡΡ, Π½Π΅ΡΠ΅Π΄ΠΊΠΎ ΡΡΠΎ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΡΠΆΠ΅Π»ΠΎΠΉ Π΄ΡΡ
Π°ΡΠ΅Π»ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ. ΠΡΠΈ ΡΡΠΎΠΌ Π²Π°ΠΆΠ½ΠΎ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΏΠΎΠΌΠΎΡΠΈ ΡΠ°ΠΊΠΈΠΌ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ, Π² Ρ. Ρ. Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅. Π¦Π΅Π»ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ²ΠΈΠ»Π°ΡΡ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠ°ΡΠΈΡ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΡΡ
Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΌΠ΅Π΄ΠΈΠΊΠ°ΠΌΠ΅Π½ΡΠΎΠ·Π½ΡΡ
ΠΈ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΏΠΎΡΠΎΠ±ΠΎΠ² Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ
(Π₯ΠΠΠ) Π½Π° ΡΠΎΠ½Π΅ Π΄Π΅ΡΠΈΡΠΈΡΠ° Ξ±1-Π°Π½ΡΠΈΡΡΠΈΠΏΡΠΈΠ½Π° (Π1ΠΠ’). Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠΏΠΎΠ»Π½Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΠΌΠ½ΠΎΠ³ΠΎΠ»Π΅ΡΠ½Π΅Π³ΠΎ Π°Π½Π°ΠΌΠ½Π΅Π·Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ Π΄Π΅ΡΠΈΡΠΈΡΠΎΠΌ Π1ΠΠ’ ΠΎΡ Π΄Π΅Π±ΡΡΠ° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π΄ΠΎ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ ΡΠ΅ΡΠΌΠΈΠ½Π°Π»ΡΠ½ΠΎΠΉ ΡΡΠ°Π΄ΠΈΠΈ Π΄ΡΡ
Π°ΡΠ΅Π»ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Π₯ΠΠΠ Π½Π° ΡΠΎΠ½Π΅ Π΄Π΅ΡΠΈΡΠΈΡΠ° Π1ΠΠ’ Π½ΡΠΆΠ΄Π°ΡΡΡΡ Π² ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΈΠ½Π³Π°Π»ΡΡΠΈΠΎΠ½Π½ΠΎΠΉ Π±Π°Π·ΠΈΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈ Π·Π°ΠΌΠ΅ΡΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠΌ Ξ±1-ΠΏΡΠΎΡΠ΅ΠΈΠ½Π°Π·Ρ. ΠΠΎ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΠΈ ΡΠ΅ΡΠΌΠΈΠ½Π°Π»ΡΠ½ΠΎΠΉ ΡΡΠ°Π΄ΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΈ ΠΏΡΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠΈ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΠΉ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΠ΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ Π»Π΅Π³ΠΊΠΈΡ
Predictors of using extracorporeal membrane oxygenation in lung transplantation
Rationale. Lung transplantation is the only definitive treatment in end-stage pulmonary disease. Extracorporeal membrane oxygenation (ECMO) has been used during surgery in recent years as a replacement for respiratory function; ECMO, however, has some drawbacks: the presence of an extracorporeal circuit, the need for heparinization, potential thrombogenicity that underlies the risks of developing specific complications that worsen the transplantation prognosis. In this regard, it is relevant to study the factors that make it possible to predict the need in intraoperative ECMO in order to avoid its unjustified use.Purpose. To identify predictors for intraoperative use of ECMO in lung transplantation.Material and methods. The medical records of patients who underwent lung transplantation in the Sklifosovsky Research Institute for Emergency Medicine from May 2011 to July 2017 were retrospectively reviewed. Forty nine bilateral lung transplantations were made where 15 patients (30.6%) had lung transplantation performed without ECMO, and 34 (69.4%) underwent lung transplantation and ECMO. A central veno-arterial connection was used in all patients. The study analyzed various factors of patient condition at baseline and identified the most significant of them that enabled to predict the need of ECMO use at surgery with a high degree of probability, avoiding episodes of gas exchange and hemodynamic impairments, the prolongation of surgery, and, therefore, the graft ischemia time.Results. As assessed in this study, pulmonary hypertension was the only predictor of an increased likelihood of using ECMO. The probability of connection to ECMO statistically significantly increased in the patients with systolic pulmonary artery pressure higher 50 mm Hg (p<0.05).Conclusion. The presence of pulmonary hypertension > 50 mm Hg determines the preventive use of ECMO during lung transplantation, which should reduce the number of uncontrolled emergencies during the main stages of surgical intervention; in all other cases, ECMO should be connected basing either on the pulmonary artery compression test results or when indicated